Investor Strategy Panel: From Specialist Therapy to Standard of Care: What Must Happen for RLTs to Become a Commercially Scalable Oncology Modality?
5:30 pm - Wednesday 2nd December 2026
- Identifying the scientific, clinical and commercial characteristics investors believe will differentiate tomorrow’s category leaders from an increasingly crowded pipeline
- Exploring which risks remain most significant to investment decisions, from manufacturing scalability and reimbursement to target differentiation and regulatory execution
- Evaluating the milestones that create the greatest enterprise value and discussing where capital should be deployed to maximise long-term commercial success
